April 30, 2020 / 12:36 PM / a month ago

BRIEF-Soligenix Announces Positive Phase 3 Flash Study Demonstrates Increased Efficacy With Continued Treatment In Patients With Cutaneous T-Cell Lymphoma

April 30 (Reuters) - Soligenix Inc:

* SOLIGENIX ANNOUNCES POSITIVE PHASE 3 FLASH STUDY DEMONSTRATES INCREASED EFFICACY WITH CONTINUED TREATMENT IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA

* SOLIGENIX - SGX301 TREATMENT RESPONSE CONTINUES TO DEMONSTRATE HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT AFTER 12 WEEKS OF THERAPY

* SOLIGENIX INC - REINFORCES POSITIVE SGX301 PRIMARY ENDPOINT TREATMENT RESPONSE DEMONSTRATING STATISTICAL SIGNIFICANCE AFTER 6 WEEKS OF THERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below